Myelodysplastic Syndrome Pipeline Insight, 2025

According to DelveInsight, over 120 key companies are actively engaged in the development of more than 125 therapeutic candidates targeting Myelodysplastic Syndrome.

Myelodysplastic Syndrome Overview:

Myelodysplastic syndrome (MDS) encompasses a group of complex blood disorders marked by the abnormal maturation of hematopoietic stem cells, leading to ineffective production of blood cells in the bone marrow. In some cases, MDS can evolve into acute myeloid leukemia (AML). The condition primarily affects individuals over the age of 65 and is typically associated with low counts of red blood cells, white blood cells, and platelets. The disease progression can vary significantly among patients.

Several factors can contribute to the development of MDS, including exposure to environmental toxins like benzene, radiation, and prior chemotherapy. However, in many older adults, the exact cause is often unclear. Furthermore, inherited or acquired bone marrow failure syndromes, such as Fanconi anemia and aplastic anemia, can increase susceptibility to MDS and may share overlapping clinical features.

Request for a detailed insights report on Myelodysplastic Syndrome pipeline insights @ https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Myelodysplastic Syndrome Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myelodysplastic Syndrome Therapeutics Market.

Key Takeaways from the Myelodysplastic Syndrome Pipeline Report

• DelveInsight’s Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Myelodysplastic Syndrome treatment.

• In January 2025, Keros Therapeutics Inc. initiated a clinical trial (KER-050-D301) to assess the efficacy and safety of elritercept (KER-050) compared to a placebo in adults with transfusion-dependent anemia associated with very low, low, or intermediate-risk Myelodysplastic Syndrome (MDS), now classified as myelodysplastic neoplasms. The study includes multiple phases: a Screening Period, a Double-Blind Treatment Period, a Safety Follow-Up Period, and a Long-Term Follow-Up Period.

• Meanwhile, Bristol-Myers Squibb launched a study to evaluate the effectiveness and safety of Luspatercept versus epoxetin alfa in treating anemia in adults with very low, low, or intermediate-risk MDS (as per IPSS-R criteria). This trial focuses on ESA-naïve patients who are non-transfusion dependent (NTD).

• Key Myelodysplastic Syndrome companies such as Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others are evaluating new drugs for Myelodysplastic Syndrome to improve the treatment landscape.

• Promising Myelodysplastic Syndrome pipeline therapies in various stages of development include Tamibarotene, CA-4948, RVU120, MNV-201, and others.

Myelodysplastic Syndrome Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Myelodysplastic Syndrome Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelodysplastic Syndrome treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Myelodysplastic Syndrome market.

Download our free sample page report on Myelodysplastic Syndrome pipeline insights @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Myelodysplastic Syndrome Emerging Drugs

• Tamibarotene: Syros Pharmaceuticals

• CA-4948: Curis

• RVU120: Ryvu Therapeutics

• MNV-201: Minovia Therapeutics

Myelodysplastic Syndrome Companies

Approximately 120 leading companies are currently engaged in developing treatments for Myelodysplastic Syndrome. Among these, Syros Pharmaceuticals stands out with a drug candidate that has reached the most advanced stage—Phase III of clinical development.

DelveInsight’s report covers around 125+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Myelodysplastic Syndrome Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Myelodysplastic Syndrome Therapies and Key Companies: Myelodysplastic Syndrome Clinical Trials and advancements @ https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Myelodysplastic Syndrome Pipeline Therapeutic Assessment

• Myelodysplastic Syndrome Assessment by Product Type

• Myelodysplastic Syndrome By Stage

• Myelodysplastic Syndrome Assessment by Route of Administration

• Myelodysplastic Syndrome Assessment by Molecule Type

Download Myelodysplastic Syndrome Sample report to know in detail about the Myelodysplastic Syndrome treatment market @ Myelodysplastic Syndrome Therapeutic Assessment @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Content

1. Report Introduction

2. Executive Summary

3. Myelodysplastic Syndrome Current Treatment Patterns

4. Myelodysplastic Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Myelodysplastic Syndrome Late-Stage Products (Phase-III)

7. Myelodysplastic Syndrome Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Myelodysplastic Syndrome Discontinued Products

13. Myelodysplastic Syndrome Product Profiles

14. Myelodysplastic Syndrome Key Companies

15. Myelodysplastic Syndrome Key Products

16. Dormant and Discontinued Products

17. Myelodysplastic Syndrome Unmet Needs

18. Myelodysplastic Syndrome Future Perspectives

19. Myelodysplastic Syndrome Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Myelodysplastic Syndrome Pipeline Reports Offerings: https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/